Reviewing Adicet Bio (NASDAQ:ACET) & Immunovant (NASDAQ:IMVT)

Adicet Bio (NASDAQ:ACET) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.

Volatility and Risk

Adicet Bio has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.

Profitability

This table compares Adicet Bio and Immunovant’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adicet Bio	N/A	-68.48%	-57.84%
Immunovant	N/A	-80.99%	-72.23%

Institutional and Insider Ownership

83.9% of Adicet Bio shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 7.8% of Adicet Bio shares are owned by insiders. Comparatively, 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Adicet Bio and Immunovant”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adicet Bio	N/A	N/A	-$117.12 million	($1.31)	-0.70
Immunovant	N/A	N/A	-$413.84 million	($2.85)	-6.75

Immunovant is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Adicet Bio and Immunovant, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adicet Bio	1	1	2	2	2.83
Immunovant	1	4	6	1	2.58

Adicet Bio currently has a consensus target price of $5.67, suggesting a potential upside of 514.67%. Immunovant has a consensus target price of $28.78, suggesting a potential upside of 49.65%. Given Adicet Bio’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Adicet Bio is more favorable than Immunovant.

Summary

Adicet Bio beats Immunovant on 11 of the 12 factors compared between the two stocks.

About Adicet Bio

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.